Member Info for Brand

I keep checking that NIH varient update that Titania shared, but still no SNG to be found under anti-virals.

Speaking of cannabis fruits, Iibe got a.mate back home that's made a proper wedge from canna stocks. I've had my eye on Oxford cannaboid since the IPO, as the idea I think is absolutely sound, but the company looks to be a S#!tshow so have steered clear.

My pleasure Woodstock. I've picked up so much from posters on this board over the last year I try and do what I can to help :)

SZ, charts not my specialty, but this seems to be the pattern when poly have been buying in the past, I think we even flatlined for 3 days straight a couple months back before the TR-1 appeared.

Nice work GGGG

Another our of the blue midday company RNS - 10/90?

Shall we discuss Synairgen's Ducks all being in a row?

The pressure on JB with covid is growing by the day. with the Jan 6th anniversary now out of the way, it would be a strong move politically to showcase the new wonder drug the US govt has been supporting.

Re Stockpiling - a quick reminder of the key finding from the UCLA peer reviewed study funded by the NIH, published in the Journal of Immunology last week.

https://www.jimmunol.org/content/208/1/74

'The key finding of this study is that the baseline IFN-ß level regulated by ORAI1-mediated Ca2+ signaling is critical for priming the cellular antiviral state, thereby determining host resistance to SARS-CoV-2 infection. A recent phase 2 clinical trial of inhaled, nebulized IFN-ß to treat people with COVID-19 resulted in accelerated recovery, supporting localized delivery of IFN-I as a potential prophylactic and therapeutic agent against COVID-19 (47). '

Prophylactic AND Therapeutic

Just to briefly once again sing the praises of the sng head of Comms. This tweet was almost definitely directed right at this board, and how well did it hit the mark hey?

Dr Mary is just as excited as the rest of us :)

https://twitter.com/MARYau_MCU_PH/status/1479087601843908610?t=WbYgWIYo78kVQlkZMEsnXw&s=19

In response to Synairgen's tweet re the partnership:

'2nd teaser.
Hope 3rd will be the press release.'

Hold hold hold. Here for the endgame.

US of course can also take on a per treatment cost of £2000 much more easily than any other market.

Genuine LOL :)

Agreed WF, look to be playing their cards perfectly :)

'Leveraging its COVID-19 experience, Ashfield Engage is supporting Synairgen as it builds its commercialisation infrastructure for the needs of SNG001, initially in the US, pending completion of pivotal trials and regulatory authorisations. This will include the recruitment of dedicated medical affairs, patient services, commercial and market access teams.'

This would look to point to SNG looking to go it alone, as opposed to JV or licensing no?

Who's going to be our copy paste hero and share the full text?

The good Doctor offering some insight on potential results

https://twitter.com/MARYau_MCU_PH/status/1478746063167270916?t=t0mcrCaDpEwtWReZaaofCA&s=19

"As SPRINTER is an admistration quite late in the disease, 0,5 should be nice.
0,8 as in phase II should be incredible drugs.
0,2 a correct addon to dexa, probably needing optimization.'

I would expect because the company weren't sitting on unblinded P3 results.

I think your bang on the money there Nice Day.

I think this rollout campaign launched back at the medi-science awards in the autumn and if you look back over the last months since, you can see Brooke's work coming together. There's the obvious stuff like the webMD interviews, but also the SSH quotes in the papers, the poster from the flu conference and so on. The Company has built a real head of steam going in to these results and all of this content will serve the company well when 'synairgen' becomes one of the most googled terms of the day.

In terms of a day of the week, with any big announcement, what your looking for is to 'own the week' leaving time for your story to be picked up and repeated across the airwaves in the following days. With this in mind I would expect a Monday or maybe Tuesday at the latest. This way you can follow up with interviews, maybe some nice shareable content on INFb or how SNG001 works over the rest of the week and in to features in the weekend media.

Understand from some of the experienced investors on here that the markets like a Monday RNS for a lot of the same reasons.